These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 19215786)

  • 41. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
    Wang L; McDonnell SK; Slusser JP; Hebbring SJ; Cunningham JM; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Res; 2007 Apr; 67(7):2944-50. PubMed ID: 17409399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
    Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
    Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
    Pearce CL; Makridakis NM; Ross RK; Pike MC; Kolonel LN; Henderson BE; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):417-8. PubMed ID: 11927504
    [No Abstract]   [Full Text] [Related]  

  • 44. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.
    Fukatsu T; Hirokawa Y; Araki T; Hioki T; Murata T; Suzuki H; Ichikawa T; Tsukino H; Qiu D; Katoh T; Sugimura Y; Yatani R; Shiraishi T; Watanabe M
    Anticancer Res; 2004; 24(4):2431-7. PubMed ID: 15330195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer.
    Elkins DA; Yokomizo A; Thibodeau SN; J Schaid D; Cunningham JM; Marks A; Christensen E; McDonnell SK; Slager S; J Peterson B; J Jacobsen S; R Cerhan J; L Blute M; J Tindall D; Liu W
    Prostate; 2003 Jun; 56(1):30-6. PubMed ID: 12746844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A common polymorphism of the SRD5A2 gene and transsexualism.
    Bentz EK; Schneeberger C; Hefler LA; van Trotsenburg M; Kaufmann U; Huber JC; Tempfer CB
    Reprod Sci; 2007 Oct; 14(7):705-9. PubMed ID: 18000232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between XRCC1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China.
    Xu Z; Hua LX; Qian LX; Yang J; Wang XR; Zhang W; Wu HF
    Asian J Androl; 2007 May; 9(3):331-8. PubMed ID: 17486273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Macrophage inhibitory cytokine-1 H6D polymorphism, prostate cancer risk, and survival.
    Hayes VM; Severi G; Southey MC; Padilla EJ; English DR; Hopper JL; Giles GG; Sutherland RL
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1223-5. PubMed ID: 16775185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy.
    Meyer A; Schürmann P; Ghahremani M; Kocak E; Brinkhaus MJ; Bremer M; Karstens JH; Hagemann J; Machtens S; Dörk T
    Urol Oncol; 2009; 27(4):373-6. PubMed ID: 18625567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of HPC2/ELAC2 polymorphism with prostate cancer risk in a Japanese population.
    Suzuki K; Ohtake N; Nakata S; Takei T; Matsui H; Ono Y; Nakazato H; Hasumi M; Koike H; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    Anticancer Res; 2002; 22(6B):3507-11. PubMed ID: 12552947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression.
    De Feo E; Persiani R; La Greca A; Amore R; Arzani D; Rausei S; D'Ugo D; Magistrelli P; van Duijn CM; Ricciardi G; Boccia S
    Mutat Res; 2009 Apr; 675(1-2):60-5. PubMed ID: 19386249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
    Scorilas A; Bharaj B; Giai M; Diamandis EP
    Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population.
    Albayrak S; Cangüven O; Göktaş C; Aydemir H; Köksal V
    Urol Int; 2007; 79(4):312-5. PubMed ID: 18025848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease.
    Ribeiro R; Vasconcelos A; Costa S; Pinto D; Morais A; Oliveira J; Lobo F; Lopes C; Medeiros R
    Prostate; 2004 May; 59(3):268-74. PubMed ID: 15042602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
    Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
    Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Y chromosome haplotypes and prostate cancer in Sweden.
    Lindström S; Adami HO; Adolfsson J; Wiklund F
    Clin Cancer Res; 2008 Oct; 14(20):6712-6. PubMed ID: 18927315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer.
    Arsova-Sarafinovska Z; Matevska N; Petrovski D; Banev S; Dzikova S; Georgiev V; Sikole A; Sayal A; Aydin A; Suturkova L; Dimovski AJ
    Cell Biochem Funct; 2008 Oct; 26(7):771-7. PubMed ID: 18646267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.